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Background: China is one of the heavy TB burden countries
with the number of TB cases ranked second in the
world. In the recent years, Although China has effectively
implemented DOTS strategy, Drug resistance-TB is one of
main constraint factors of TB control in China.
Objectives: To study the trends of drug resistant
tuberculosis prevalence in China.
Methods: The data from 1996 to 2006 in 13 provinces
(WHO/IUATLD drug resistance surveillance (DRS) project)
of which standardized method recommended by WHO in
sampling, cases intake, laboratory examination methods
were used to analyze the drug resistance prevalence
situation in survey regions. Results The data show that the
drug-resistant tuberculosis varied widely across different
provinces of China, initial drug resistance rate and
acquired drug resistance rate were 14.8 42.1% and 33.7 66%
respectively.
Conclusion: Drug resistant-TB prevalence is severe problem
in some regions of China. Effective measure should be
taken to contain the transmission of drug resistance strains
of tuberculosis, Nationwide anti-TB drug resistance survey
seems to be needed to investigate the situation of drug
resistance situation of whole country to provide scientiﬁc
basis on evaluation the implementation of the NTP.
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Academic and clinical investigators have continuously
sought for prognostic or surrogate markers can monitor
T-cell immune responses following viral infections, tumors,
autoimmune disease, bone marrow transplantation, and
especially in monitoring efﬁcacy of vaccines and treatment
therapies. We have recently developed a novel T-cell
receptor (TCR) clonality/diversity assay in human and
animal models for this purpose. The method is specially
designed with one step multiple-PCR ampliﬁcations and a
simple agarose gel assay. The most important features of
the assay are that they require neither a DNA-sequencer nor
an initial cDNA synthesis step. The entire process requires
only a few hours, including PCR ampliﬁcation time, by
comparison, the DNA sequencer-based spectratyping assay
requires at least 2 or 3 days to complete, and costs are
much lower. As an investigative tool, the novel assay can be
used to study various diseases related to immune-mediated
disorders including viral infections, tumors, autoimmune
diseases, immune response following vaccination, and
response after bone marrow transplantation. As a diagnostic
tool, it can be used to monitor disease progression and track
curative effects of antiviral or anti-tumor treatments.
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Multidrug-resistance pumps (MDR) in microbes and cancer
cells are powerful defense mechanisms which confer
resistance to chemically unrelated drugs. A major challenge
in developing efﬁcacious antibiotics against drug-resistant
pathogens is to identify compounds that could sense, inhibit
and counteract MDR functions. In the human pathogen
Candida albicans, MDR1p plays a key role in clinical isolates
with azole-resistance. Here we report an unexpected
function of MDR1 in elevating the sensitivity of fungal
pathogen to berberine for enhanced therapeutic efﬁcacy.
Berberine, a widely used traditional Chinese medicine
identiﬁed as a potent fungicidal cofactor from our high
throughput synergy screening (PNAS 2007; 104: 4606),
is highly active against azole-resistant fungal pathogens.
It appears that the elevated expression of MDR1 in
resistant fungal strains confers sensitivity to berberine,
showing enhanced cell killing with much reduced amount
of berberine (Fig 1). This effect of MDR1 overexpression
is at least in part attributed to enhanced accumulation
of berberine. In support of this notion, a number of
berberine structural analogues exhibited a similar MDR1-
dependent antifungal activity (Fig 2). Berberine is indeed
highly efﬁcacious in inhibiting the growth of azole-resistant
clinical C. albicans isolates with upregulated MDR1 from
HIV infected patients. It seems that nature outsmarted
the defense mechanisms of fungal pathogen by using
MDR1-dependent cytotoxic agents like berberine and its
analogues. Our study reveals a novel function of MDR1
in raising sensitivity of drug-resistant fungal pathogens to
selected natural products and thus shed lights on novel
antifungal therapy.
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